EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Direct Second Autologous Stem Cell Transplantation Versus Re-Induction Followed by Transplantation in Relapsed Multiple Myeloma: A Multicenter Real-World Study

Taha Ulutan Kars iD, Hakan Göker, Haluk Demiroğlu, Ümit Yavuz Malkan iD, Elifcan Aladağ Karakulak, Fatma Tuğba Erdekli, Burak Deveci, Süreyya Yiğit Kaya iD, Leylagül Kaynar iD, Asena Dikyar, Sait Emir Şahin, Metin Bağcı iD und 4 weitere

Journal of Clinical Medicine · 28.06.2026 · 15 (13) · 5045

DOI: 10.3390/jcm15135045 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 28.06.2026. Verfasst von Taha Ulutan Kars und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Konya City Hospital, 42040 Konya, Türkiye. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Whether patients with relapsed multiple myeloma (MM) should proceed directly to a second autologous stem cell transplantation (ASCT2) or receive re-induction chemotherapy beforehand remains uncertain. In real-world practice, treatment allocation is highly heterogeneous, and comparative data addressing the impact of pre-ASCT2 strategy on survival outcomes are limited, partly because ASCT2 is reserved for selected patients and is not routinely performed in all relapsed MM cases. We aimed to evaluate real-world outcomes of ASCT2 performed either directly at relapse or following re-induction chemotherapy in patients with relapsed MM, with a focus on progression-free survival after ASCT2 (PFS2) and overall survival (OS).

Methods

We conducted a multicenter retrospective cohort study including 42 patients with relapsed MM who underwent ASCT2 between 2012 and 2024 across eight centers. Patients were grouped according to pre-ASCT2 management: those proceeding directly to ASCT2 without additional systemic therapy (direct-ASCT2, n = 21) and those receiving ≥ 1 line of salvage chemotherapy prior to ASCT2 (re-induction, n = 21). Survival outcomes were estimated using Kaplan–Meier methods and explored using multivariable Cox regression analyses.

Results

The median PFS2 for the entire cohort was 19.7 months (95% CI, 7.8–31.6), with no statistically significant difference between the direct-ASCT2 and re-induction groups (21.3 vs. 13.8 months; p = 0.790). Median OS was 48.2 months (95% CI, 41.3–55.1). Although OS was significantly longer in the unadjusted analysis (51.7 vs. 39.6 months; p = 0.019), this difference was not maintained after multivariable adjustment. Post-ASCT2 response rates were comparable between groups, and day-100 transplant-related mortality was low at 2.4%.

Conclusions

In this multicenter real-world cohort, pre-ASCT2 re-induction chemotherapy was not associated with a clear improvement in PFS2 compared with proceeding directly to ASCT2. Observed differences in unadjusted OS likely reflect confounding by indication and selection bias inherent to retrospective treatment allocation. These findings should therefore be interpreted as hypothesis-generating, but they add to the limited real-world evidence base on ASCT2, a salvage strategy that is typically applied to highly selected patients.

Schlagwörter

Stichwörter der Autor:innen

autologous transplantationmultiple myelomare-inductionrelapsesalvage therapysurvival

Autor:innen und Institutionen

  • Division of Hematology, Konya City Hospital, 42040 Konya, Türkiye.
  • Division of Hematology, Faculty of Medicine, Hacettepe University, 06100 Ankara, Türkiye.
  • Division of Hematology, Medstar Hospital, 06100 Antalya, Türkiye.
  • Division of Hematology, Faculty of Medicine, Medipol University, 34083 İstanbul, Türkiye.
  • Division of Hematology, Etlik City Hospital, 06100 Ankara, Türkiye.
  • Department of Internal Medicine, Antalya Training and Research Hospital, 06100 Antalya, Türkiye.

ORCID-Profile: Taha Ulutan Kars, Ümit Yavuz Malkan, Süreyya Yiğit Kaya, Leylagül Kaynar, Metin Bağcı, Buğra Sağlam, Ahmet Kürşad Güneş, Ömür Gökmen Sevindik, Volkan Karakuş

Zitieren

APA

Kars, T. U., Göker, H., Demiroğlu, H., Malkan, Ü. Y., Aladağ Karakulak, E., Erdekli, F. T., Deveci, B., Yiğit Kaya, S., Kaynar, L., Dikyar, A., Şahin, S. E., Bağcı, M., Sağlam, B., Güneş, A. K., Sevindik, Ö. G., & Karakuş, V. (2026). Direct Second Autologous Stem Cell Transplantation Versus Re-Induction Followed by Transplantation in Relapsed Multiple Myeloma: A Multicenter Real-World Study. Journal of Clinical Medicine, 15(13), 5045. https://doi.org/10.3390/jcm15135045

Vancouver

Kars TU, Göker H, Demiroğlu H, Malkan ÜY, Aladağ Karakulak E, Erdekli FT, et al. Direct Second Autologous Stem Cell Transplantation Versus Re-Induction Followed by Transplantation in Relapsed Multiple Myeloma: A Multicenter Real-World Study. Journal of Clinical Medicine. 2026;15(13):5045. doi:10.3390/jcm15135045

BibTeX
@article{Kars2026,
  author = {Kars, Taha Ulutan and Göker, Hakan and Demiroğlu, Haluk and Malkan, Ümit Yavuz and Aladağ Karakulak, Elifcan and Erdekli, Fatma Tuğba and Deveci, Burak and Yiğit Kaya, Süreyya and Kaynar, Leylagül and Dikyar, Asena and Şahin, Sait Emir and Bağcı, Metin and Sağlam, Buğra and Güneş, Ahmet Kürşad and Sevindik, Ömür Gökmen and Karakuş, Volkan},
  title = {Direct Second Autologous Stem Cell Transplantation Versus Re-Induction Followed by Transplantation in Relapsed Multiple Myeloma: A Multicenter Real-World Study},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {13},
  pages = {5045},
  doi = {10.3390/jcm15135045}
}
Kostenlos starten →